《大行報告》美銀證券下調中國飛鶴(06186.HK)目標價至18元 評級「買入」
美銀證券發表報告指,由於行業趨勢惡化,對內地嬰兒配方奶粉的前景看法更為審慎,將中國飛鶴(06186.HK)股份目標價由21元降至18元,並調低明年及2023年每股盈利預測3%。不過,該行認為集團面對行業挑戰相對有防守性,因此投資評級維持「買入」。
美銀表示,在競爭加劇及正在下行的市場環境中,執行力是至為重要,而中國飛鶴已證明其繼續達至市佔率增長的能力,主要是受有效的客戶獲取,及嚴格控制分銷成本所推動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.